Furthermore, CMArg@Lip exerts immunomodulatory effects within the immunosuppressed TME through three main mechanisms: 1) induction of ferroptosis via CMArg@Lip leads to enhanced ICD; 2) ML385 effectively mitigates the restriction of immune checkpoint blockade on CTLs, as it prevents PDT‐induced upregulation of PD‐L1; 3) CMArg@Lip activates the stimulator of interferon genes (STING) signaling pathway in MDSCs within the TME, resulting in the loss of CTL inhibition and a shift toward an immunostimulatory phenotype that fosters anti‐tumor immunity. Here, STING1 is linked to neoplasm.